Latest .bd Stories
FRANKLIN LAKES, N.J., May 22, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 45 cents per common share, payable on June 29, 2012 to holders of record on June 8, 2012. The indicated annual dividend rate is $1.80 per share. About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to...
FRANKLIN LAKES, N.J. and OLATHE, Kan., May 21, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Heart to Heart International, a humanitarian medical aid nonprofit organization, are teaming up for their second joint volunteer initiative to strengthen healthcare in Haiti. A team of 16 BD employees from around the world will build upon the progress made by their colleagues in 2011 during BD's first Volunteer Service...
FRANKLIN LAKES, N.J., May 2, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in May 2012: Deutsche Bank Securities 37th Annual Health Care ConferenceMay 7, 201210:00 a.m. ET Bank of America Merrill Lynch Annual Health Care ConferenceMay 15, 20125:20 p.m. ET Live webcasts of BD's presentations can be accessed on the BD corporate...
FRANKLIN LAKES, N.J., April 2, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2012 earnings conference call on Tuesday, May 1, 2012, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning. The webcast of the conference call, along with related slides, will be accessible through BD's website at www.bd.com/investors and will be available...
BALTIMORE, March 28, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the U.S. Food and Drug Administration (FDA) clearance of the BD MAX(TM) Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX(TM) System. The BD MAX GBS Assay is an in vitro diagnostic (IVD) test for detection of GBS DNA in Lim Broth cultures - enabling laboratories to...
FRANKLIN LAKES, N.J., March 9, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Barclays Capital Global Healthcare Conference on Tuesday, March 13, 2012, at 2:00 p.m. (ET). A live webcast of BD's presentation can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Tuesday, March 20, 2012. About BD BD is a leading global...
FRANKLIN LAKES, N.J., Feb. 13, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired KIESTRA Lab Automation BV, a Netherlands-based company that designs, develops, manufactures, markets and sells innovative lab automation solutions for the microbiology lab. The financial terms of the acquisition were not disclosed. The transaction is expected to be slightly dilutive; however, BD...
FRANKLIN LAKES, N.J., Feb. 10, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in February 2012: Leerink Swann 2012 Global Healthcare ConferenceFebruary 15, 201210:30 a.m. ET Citi 2012 Global Healthcare ConferenceFebruary 28, 201210:00 a.m. ET Live webcasts of BD's presentations can be accessed on the BD corporate website at...
BILLERICA, Mass., Feb. 8, 2012 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic(TM) Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell culture environment for human mesenchymal stem cells (hMSCs) derived from bone marrow. The BD Mosaic hMSC cell culture environment is designed to provide cell expansion in a shorter culture time--about half the time of traditional serum-based...
FRANKLIN LAKES, N.J., Jan. 31, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 45 cents per common share, payable on March 30, 2012 to holders of record on March 9, 2012. The indicated annual dividend rate is $1.80 per share. About BD BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to...
